Introduction
============

Stroke is the second-leading cause of death in the world and the leading cause of death in China.[@b1-ppa-10-2419]--[@b4-ppa-10-2419] In 2013, more than 1.9 million Chinese adults died from stroke, which represented an increase of 47.7% from 1.3 million in 1990.[@b4-ppa-10-2419] Hypertension is the most important risk factor for stroke.[@b5-ppa-10-2419] About 54% of strokes worldwide were attributable to high blood pressure (BP), and about 80% of the attributable burden occurred in low- or middle-income countries.[@b6-ppa-10-2419] To date, an estimated 0.2 billion people had hypertension in China, accounting for a fifth of the total hypertensive population in the world. The rising incidence of stroke and hypertension has created a heavy burden to the Chinese health care system.

American,[@b7-ppa-10-2419] European,[@b8-ppa-10-2419] and Japanese[@b9-ppa-10-2419] hypertension guidelines have confirmed the importance of ambulatory BP monitoring (ABPM) and home BPM (HBPM). Most studies[@b10-ppa-10-2419]--[@b13-ppa-10-2419] on stroke still use BP values based on traditional office measurements, rather than ABPM or HBPM. Moreover, BP lowering in the acute phase of ischemic stroke (IS) and secondary prevention has been a longstanding controversy.[@b14-ppa-10-2419],[@b15-ppa-10-2419] It is not clear when the optimal time is to initiate early BP lowering or what the target-BP level is in IS and transient ischemic attack (TIA) patients. There are few BP databases[@b16-ppa-10-2419],[@b17-ppa-10-2419] for IS patients worldwide to date. As far as we know, China, which has a fifth of the world's population, still lacks a BP database for IS and TIA patients. Given this, we performed a nationwide prospective investigation on BP parameters and clinical outcomes in our cohort of patients with acute IS or TIA from 2012 in 61 hospitals, and 1-year follow-up data of all 2,068 patients was completed in 2015. In this report, we introduce the rationale, study design, and the baseline characteristics of BOSS (blood pressure and clinical outcome in TIA or ischemic stroke).

Materials and methods
=====================

Study design
------------

BOSS was a nationwide, hospital-based, longitudinal cohort study aiming to assess BP parameters and clinical outcome in IS/TIA patients, conducted at 61 hospitals in China. The participating hospitals were mainly tertiary urban hospitals, selected from 16 provinces and four municipalities across mainland China, including Northeast China (Heilongjiang, Jilin, Liaoning), Northwest China (Shaanxi), North China (Beijing, Tianjin, Hebei, Shanxi, Inner Mongolia), East China (Shanghai, Shandong, Jiangsu, Fujian, Zhejiang), South-central China (Henan, Hubei, Guangdong), and Southwest China (Chongqing, Sichuan). The details of centers are shown in [Table S1](#SD2-ppa-10-2419){ref-type="supplementary-material"}. A total of 2,720 IS/TIA patients were consecutively enrolled from October 2012 to February 2014. An average of 42.5 participants were enrolled in each center. The study was approved by the central Institutional Review Board at Beijing Tiantan Hospital, and all patients or their designated relatives provided written informed consent. Electronic case-report forms were used to record baseline and follow-up data. The patients were followed up at 3 months through face-to face interview and at 12 months by telephone.

BP measurement
--------------

Office BP (OBP) was measured by doctors or trained nurses according to a standard measurement method recommended by the American Heart Association[@b18-ppa-10-2419] at admission, discharge, and 3-month visit. After enrollment, each patient was assigned a semiautomatic upper-arm BP monitor (HEM-4030; Omron, Kyoto, Japan), and patients or their accompanying relatives were trained by nurses to use it. During hospitalization, BP would be measured twice daily by patients themselves or their relatives, and BP data were recorded in an assigned hospitalization BP diary. Moreover, ABPM was also completed during hospitalization. BP measurements were taken every 15 minutes during the day and every 30 minutes at night. Daytime episodes were defined from 6 am to 9:59 pm and nighttime episodes from 10 pm to 5:59 am. If the recorded BP readings are less than 80% of expected measurements, the ABPM should be repeated. Sleep diaries were compiled by patient self-report, including sleep time and awake time. At discharge, the assigned Omron BP monitor was taken home by patients. Patients would persist on measuring BP twice daily at home from the first day after discharge to 3 months after onset, and once a day from 3 months to 12 months after onset, and all BP data were recorded on the assigned home BP diaries ([Figure S1](#SD1-ppa-10-2419){ref-type="supplementary-material"}). For patients with atrial fibrillation, they did not need to complete ABPM, and all of them were assigned a mercury sphygmomanometer to monitor home BP, rather than a semiautomatic monitor, because oscillometric devices may not record BP accurately in patients with arrhythmias.[@b19-ppa-10-2419],[@b20-ppa-10-2419]

Inclusion criteria and baseline and follow-up data collection
-------------------------------------------------------------

Patients were recruited consecutively if the following conditions were met: age of 18 years or older, diagnosis of an acute IS or TIA, and within 7 days of the index event. TIA was defined as new symptomatic neurologic deterioration lasting less than 24 hours with no new infarction on neuroimaging. Acute IS was diagnosed according to World Health Organization criteria combined with brain computed tomography or magnetic resonance imaging confirmation.[@b21-ppa-10-2419]

A standard electronic data-collection system was developed by Goodwill Information Technology Co Ltd, and the electronic case-report forms were used for baseline and follow-up data collection. All research coordinators and investigators were trained how to use this electronic data-collection system before the trial-kickoff meeting.

Baseline information included demographics, risk factors, medication use, diagnosis, disease management, and discharge status. Risk factors were defined as follows: history of hypertension (a reported history of hypertension or antihypertensive medication use), history of stroke (defined as a medical chart-confirmed history of stroke, including IS, intracerebral hemorrhage, or subarachnoid hemorrhage), coronary heart disease (a reported history of myocardial infarction or cardiac surgery, or with a final diagnosis of myocardial infarction at discharge), atrial fibrillation (a reported history of atrial fibrillation or diagnosed using the patient's in-hospital electrocardiogram), diabetes mellitus (self-reported physician diagnosis of diabetes mellitus or use of antidiabetic drugs), dyslipidemia (self-reported physician diagnosis of dyslipidemia or use of lipid-lowering agents), current or previous smoking (defined as an individual who was a smoker at the time of the stroke or had quit smoking within 1 year), moderate or heavy drinking (two or more standard alcoholic beverages consumed per day), body mass index (calculated as measured weight divided by the square of measured height). Other clinical features included prestroke modified Rankin scale (mRS), National Institutes of Health Stroke Scale (NIHSS) score at admission and discharge, IS subtypes according to the TOAST criteria (large-artery atherosclerosis, small-artery occlusion, cardioembolism, stroke of other determined etiology, and stroke of undetermined etiology). Treatment information included medication use during hospitalization and medication with discharge (antiplatelet, anticoagulant, antihypertensive, antidiabetic, and statin medication).

Follow up information included OBP, clinical outcomes, and medication adherence. Clinical outcomes included death, disability, and vascular events. Death was assessed by vascular death (including fatal stroke, fatal myocardial infarction, and other cardiovascular death) or death for any causes. Disability was measured by the mRS from 0 to 5 (death was rated as 6) and was defined as mRS 3--5. Vascular events included stroke or TIA recurrence, myocardial infarction, heart failure, and vascular operation. Recurrent stroke was defined as a new stroke event (ischemic or hemorrhagic) or rapid worsening of an existing focal neurologic deficit lasting more than 24 hours (an increase in the NIHSS score by ≥4 points compared with baseline NIHSS score), accompanied by new ischemic changes on magnetic resonance imaging or computed tomography of the brain.[@b22-ppa-10-2419]

Statistical analyses
--------------------

In this article, analyses focused on patient baseline characteristics and describing the BP parameters. For descriptive analysis, proportions were used for categorical variables, and means with standard deviations were used for continuous variables. Data were analyzed using SAS version 9.1.3 statistical software (SAS Institute, Cary, NC, USA).

Results
=======

From October 2012 to February 2014, 2,720 IS/TIA patients from 64 hospitals were registered. Three hospitals were eliminated because most of their enrolled patients did not complete ABPM or HBPM, so all 109 patients enrolled in these three hospitals were excluded. Moreover, three patients were removed, because their baseline information were absent. We included a total of 2,608 consecutive patients as our cohort.

We followed up the cohort patients for 1 year; 82 (3.1%) patients were lost to follow-up at 3 months, and 132 (5.1%) patients were lost to follow-up at 1 year. A detailed patient-recruitment flowchart is illustrated in [Figure 1](#f1-ppa-10-2419){ref-type="fig"}. Of 2,608 patients, the mean age was 62.5 years, 32.4% were females, 88.9% had an entry diagnosis of IS, and 86% was diagnosed with hypertension. Other characteristics are summarized in [Table 1](#t1-ppa-10-2419){ref-type="table"}.

[Table 2](#t2-ppa-10-2419){ref-type="table"} shows the BP parameters based on OBP, ABP, and HBP. Mean OBP was 150.53±20.67/86.44±12.58 mmHg at admission, 136.94±13.89/80.29±9.71 mmHg at discharge, 134.51±11.94/80.52±8.60 mmHg at the 3-month visit. Visit-to-visit systolic BP (SBP) variability based on OBP was 13.11±9.05 mmHg, 24-hour SBP variability based on ABPM was 15.35±4.42 mmHg, and day-to-day SBP variability based on HBPM was 8.62±4.1 mmHg. ABP data showed that 70% of patients had morning hypertension, 51.1% had nocturnal hypertension, and 27.7% were reverse dippers.

Medication information is described in [Table 3](#t3-ppa-10-2419){ref-type="table"}. Proportions of antihypertensive medication during hospitalization, at discharge, and at 3 months were 65.9%, 68.5%, and 67.6%; 93% of patients completed ABP monitoring, 94.7% of patients completed their 3-month BP diary. Detailed information about ABPM- and BP-diary completion is reported in [Table 4](#t4-ppa-10-2419){ref-type="table"}. As to clinical outcomes, rates of stroke recurrence, combined vascular events, and mortality are listed in [Table 5](#t5-ppa-10-2419){ref-type="table"}.

Discussion
==========

To our knowledge, BOSS is the first nationwide BP database including the most comprehensive BP information for IS/TIA patients in China, and will provide important BP parameters for further investigation in the management of acute IS and secondary prevention of IS. There were three types of BP monitoring in this study: OBPM, ABPM, and HBPM. Because ABPM offers specific advantages over OBPM, such as providing a much larger number of readings, identifying white-coat and masked hypertension phenomena, and supplying nocturnal hypertension and dipping patterns, European Society of Hypertension practice guidelines for ABPM[@b23-ppa-10-2419] point out that ABPM improves prognostic accuracy in target-organ damage and cardiovascular morbidity and mortality compared with OBPM. However, to date most stroke studies[@b24-ppa-10-2419]--[@b27-ppa-10-2419] still use OBPM, and we found that the conclusion of these studies about the relationship between BP level and stroke outcomes remains controversial, especially for IS/TIA patients. It is urgent to establish a large ABPM database in relation to stroke outcome, like IDACO (international database of ambulatory blood pressure in relation to cardiovascular outcome).[@b16-ppa-10-2419] BOSS has an independent and complete ABPM database, in which there are 93% of total patients and more than 85% of patients with at least 80% of expected measurements during 24-hour recording.

HBPM is also recommended by guidelines.[@b7-ppa-10-2419]--[@b9-ppa-10-2419] HBPM seems to be more closely associated with hypertensive end-organ damage than clinic BP, even for a low number of measurements. In BOSS, uniform devices were used to measure home BP to avoid measurement error. In addition, BP data were recorded on each day, so BP variation could be calculated as day-to-day variability, rather than visit-to-visit variability, which was used in most previous studies.[@b28-ppa-10-2419]--[@b30-ppa-10-2419] It is worth noting that the completion rate of the 3-month BP diary was as high as 94.7%, which could supply high-quality data to calculate BP parameters.

In addition, adherence to secondary prevention medication in IS and TIA patients was another focus in BOSS. Adherence was defined in consistence with the AVAIL study,[@b31-ppa-10-2419] which provided the possibility of comparison of medication adherence of secondary prevention between Chinese and American patients.

Fortunately, the rate of loss to follow-up of BOSS was only 3.1% at 3 months and 5.1% at 1 year, which can offer credible event outcomes. However, we found the event rate of BOSS to be much lower than historical cohorts, eg, the 1-year risk of stroke in historical cohorts was 17.7% in CNSR,[@b24-ppa-10-2419] 12.3% in CHANCE,[@b32-ppa-10-2419] and 12.2% in SAMMPRIS[@b33-ppa-10-2419] compared with 6.1% in our cohort. It is worth noting that recently the [TIAregistry.org](http://TIAregistry.org) project[@b34-ppa-10-2419] also reported a very low risk of stroke after a TIA or minor stroke: 3.7% at 90 days and 5.1% at 1 year after symptom onset, which is close to our cohort. The lower event rates in our cohort may be explained HBPM improving not only BP-medication adherence but also overall compliance with secondary prevention treatment. Our study showed that adherence rates of antiplatelet, statin, and antihypertensive medication use at 3 months were similar to the rates at discharge (see [Table 3](#t3-ppa-10-2419){ref-type="table"}).

This registry has potential limitations. The first limitation is the different type of device and analysis software for ABPM used in each site. Given this, the original BP data of all of the patients were re-entered in EpiData and all of the BP-composite parameters were recalculated using SAS software. Second, although 94.7% of patients completed 3-month BP diary in this study, only 40% of the patients returned their diaries for recording HBP from 3 months to 1 year after symptom onset. Third, telephone but not face-to-face follow-up was adopted at 1 year. For patients with clinical events at 1-year telephone follow-up, we would further confirm this event. Each case fatality was either confirmed on a death certificate from the local citizen registry or from the attended hospital. In cases of lack of local citizen-registry information or death without hospitalization, case fatality was deemed to be reliable if death was reported on two consecutive follow-up periods from different proxies. We would call back patients with nonfatal events for a face-to-face follow-up or carry out a home visit. Fourth, according to the protocol of this registry, all patients were required to be consecutively enrolled. However, in consideration of HBP monitoring, more mild patients were recruited, which would lead to a selection bias. Fifth, this was a mainly ethnically Chinese cohort, which did not include white and black people.

Conclusion
==========

This study introduced the design, rationale, and baseline characteristics of BOSS, which was a nationwide, hospital-based, longitudinal cohort study aiming to assess BP parameters (based on OBPM, ABPM, and HBPM) and clinical outcome in IS/TIA patients. The BOSS registry will provide important evidence about BP management in the acute phase and secondary prevention for IS/TIA patients.

Supplementary materials
=======================

###### 

Design of the BOSS study.

**Abbreviations:** BOSS, blood pressure and clinical outcome in TIA or ischemic stroke; BP, blood pressure; OBP, office BP; ABPM, ambulatory BP monitoring; HBPM, home BPM; TIA, transient ischemic attack.

###### 

Participating hospital information

  Location                  Name                                                                 Grade   PI
  ------------------------- -------------------------------------------------------------------- ------- -------------------
  **North China**                                                                                        
  Beijing                   Beijing Tiantan Hospital, Capital Medical University                 III     Xingquan Zhao
  Beijing                   Beijing An Zhen Hospital, Capital Medical University                 III     Qi Bi
  Beijing                   Beijing Friendship Hospital                                          III     Jimei Li
  Beijing                   Third Hospital of Peking University                                  III     Dongsheng Fan
  Beijing                   Beijing Hospital                                                     III     Tao Gong
  Beijing                   People's Hospital of Peking University                               III     Xuguang Gao
  Hebei                     Second Hospital of Hebei Medical University                          III     Guohua Zhang
  Hebei                     First Hospital of Handan                                             III     Yiping Wu/Jie Lin
  Hebei                     Cangzhou Central Hospital                                            III     Junling Zhang
  Hebei                     Shijiazhuang Central Hospital                                        III     Wanying Shi
  Hebei                     Third Hospital of Hebei Medical University                           III     Junyan Liu
  Hebei                     People's Hospital of Hebei                                           III     Peiyuan Lv
  Inner Mongolia            Baogang Hospital                                                     III     Dong Wang
  Shanxi                    Second Hospital of Shanxi Medical University                         III     Guanglai Li
  Shanxi                    Changzhi People's Hospital                                           III     Lili Zhao
  Tianjin                   Fourth Central Hospital of Tianjin                                   III     Chunling Ji
  Tianjin                   Tianjin Huanhu Hospital                                              III     Yong Ji
  Tianjin                   Tianjin Binhai People's Hospital                                     II      Bin Li
  **Northeast China**                                                                                    
  Heilongjiang              First Machine Factory Workers Hospital of Qiqihar                    II      Chunling Yang
  Jilin                     Jilin Central Hospital                                               III     Hanyi Zhang
  Jilin                     First Hospital of Jilin University                                   III     Jiachun Feng
  Liaoning                  First Hospital of Liaoning Medical University                        III     Rubo Sui
  Liaoning                  Hospital of Dalian Economic and Technological Development Zone       II      Ying Lian
  **Northwest China**                                                                                    
  Shaanxi                   Xi'an 141 Hospital                                                   II      Qiuwu Liu
  **East China**                                                                                         
  Fujian                    Xiamen Second Hospital                                               III     Jianping Niu
  Jiangsu                   First Hospital of Suzhou University                                  III     Zhuan Xu
  Jiangsu                   Second Hospital of Suzhou University                                 III     Heqing Zhao
  Jiangsu                   Nanjing First Hospital                                               III     Junshan Zhou
  Jiangsu                   Lianyungang Traditional Chinese Medicine Hospital                    III     Lejun Li
  Jiangsu                   Gulou Hospital of Nanjing University Medical College                 III     Zhongyuan Wang
  Shandong                  People's Hospital of Zibo Linzi                                      III     Yongliang Cao
  Shandong                  Affiliated Hospital of Qingdao University                            III     Xudong Pan
  Shandong                  Hospital of Shandong Province                                        III     Yifeng Du
  Shanghai                  East Hospital of Yangpu District                                     II      Fei Li
  Shanghai                  Shanghai Tongji Hospital                                             III     Zhiyu Nie
  Shanghai                  Central Hospital of Shanghai Yangpu                                  III     Xin Li
  Shanghai                  Sixth People's Hospital of Shanghai Jiaotong University              III     Xiaojiang Sun
  Shanghai                  Branch of Shanghai First People's Hospital                           II      Shaoshi Wang
  Shanghai                  Public Hospital of Shanghai Pudong New Area                          II      Xuelian Yang
  Shanghai                  Xinhua Hospital of Shanghai Jiaotong University Medical Department   III     Zhenguo Liu
  Shanghai                  Ruijin Hospital of Shanghai Jiaotong University Medical Department   III     Shengdi Chen
  Zhejiang                  First People's Hospital of Taizhou                                   III     Zhimin Wang
  Zhejiang                  First Hospital of Wenzhou Medical University                         III     Chengye Zhou
  Zhejiang                  First Hospital of Zhejiang University Medical College                III     Benyan Luo
  Zhejiang                  Hangzhou First Hospital                                              III     Guozhong Niu
  Zhejiang                  Shaoyifu Hospital of Zhejiang University Medical College             III     Xingyue Hu
  Zhejiang                  No 2 Hospital of Zhejiang University Medical College                 III     Baorong Zhang
  **South-central China**                                                                                
  Guangdong                 Jiangmen Central Hospital                                            III     Jianxin Zhong
  Guangdong                 First Hospital of Jinan University                                   III     Anding Xu
  Guangdong                 First People's Hospital of Foshan                                    III     Yukai Wang
  Guangdong                 First People's Hospital of Guangzhou                                 III     Xiaoping Pan
  Guangdong                 Third Hospital of Zhongshan University                               III     Zhengqi Lu
  Guangdong                 Zhujiang Hospital                                                    III     Zhenhua Liu
  Guangdong                 People's Hospital of Shenzhen                                        III     Xiaofan Chu
  Henan                     First Hospital of Zhengzhou University                               III     Yuming Xu
  Hubei                     Wuhan Union Hospital, Tongji Medical College of HUST                 III     Yuanjin Guo
  Hubei                     Wuhan Neurosurgical Hospital                                         III     Yuhua Chen
  Hubei                     Wuhan First Hospital                                                 III     Guohua Chen
  Hubei                     Wuhan Zhongshan Hospital                                             III     Xiaorong Deng
  Hubei                     Xinhua Hospital of Hubei                                             III     Kang Xu
  **Southwest China**                                                                                    
  Sichuan                   Third People's Hospital of Chengdu                                   III     li Gao
  Sichuan                   People's Hospital of Sichuan                                         III     Wenbin Wu
  Chongqing                 Daping Hospital of Third Military Medical University                 III     Huadong Zhou
  Chongqing                 First Hospital of Third Military Medical University                  III     Kangning Chen

**Abbreviations:** PI, principal investigator; HUST, Huazhong University of Science and Technology.
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###### 

Baseline characteristics of the study population

  Variable                                          All (n=2,608)       Missing
  ------------------------------------------------- ------------------- ----------
  **Stroke subtype**                                                    0
  IS                                                2,318 (88.9)        
  TIA                                               290 (11.1)          
  Female                                            845 (32.4)          0
  Age (years)                                       62.5±11.1           0
  Current or previous smoker                        1,124 (43.2)        4 (0.2)
  Moderate or heavy drinking                        451 (17.3)          4 (0.2)
  Body mass index, median (Q1--Q3)                  24.6 (22.9--26.6)   92 (3.5)
  History of hypertension                           1,837 (70.6)        4 (0.2)
  History of stroke                                 618 (23.8)          6 (0.2)
  History of TIA                                    102 (3.9)           6 (0.2)
  Hypertension with discharge diagnosis             2,238 (86)          7 (0.3)
  Diabetes mellitus with discharge diagnosis        739 (28.4)          7 (0.3)
  Dyslipidemia with discharge diagnosis             1,083 (41.7)        8 (0.3)
  Coronary heart disease with discharge diagnosis   328 (12.6)          8 (0.3)
  Atrial fibrillation with discharge diagnosis      104 (4)             7 (0.3)
  NIHSS score on admission                          3.1±3.4             49 (1.9)
  **Ischemic stroke subtype**                                           19 (0.7)
  Large-artery atherosclerosis                      1,358 (59.1)        
  Cardioembolism                                    89 (3.9)            
  Small-artery occlusion                            776 (33.8)          
  Other                                             76 (3.3)            

**Abbreviations:** IS, ischemic stroke; NIHSS, National Institute of Health Stroke Scale; SD, standard deviation; TIA, transient ischemic attack.

###### 

BP parameters based on OBP, ABP, and HBP

  Variable                            All (n=2,608)   Missing
  ----------------------------------- --------------- -----------
  **OBP**                                             
  SBP on admission                    150.5±20.7      50 (1.9)
  SBP at discharge                    136.9±13.9      39 (1.5)
  SBP at 3 months                     134.5±11.9      225 (8.6)
  DBP on admission                    86.4±12.6       50 (1.9)
  DBP at discharge                    80.3±9.7        41 (1.6)
  DBP at 3 months                     80.5±8.6        225 (8.6)
  **Visit-to-visit BP variability**                   
  Systolic, mmHg                      13.1±9.1        17 (0.7)
  Diastolic, mmHg                     7.8±5.5         17 (0.7)
  **ABP**                                             
  **Average 24-hour BP**                              
  Systolic, mmHg                      141.7±18.2      182 (7)
  Diastolic, mmHg                     84±13           182 (7)
  Average 24-h HR, bpm                69.9±9.6        185 (7.1)
  **Average daytime BP**                              
  Systolic, mmHg                      143±18.3        182 (7)
  Diastolic, mmHg                     85.1±13.3       182 (7)
  Average daytime HR, bpm             71.4±9.8        185 (7.1)
  **Average nighttime BP**                            
  Systolic, mmHg                      137.4±20.4      213 (8.2)
  Diastolic, mmHg                     80.4±13.4       213 (8.2)
  Average nighttime HR, bpm           64.9±9.9        216 (8.3)
  Morning hypertension, n (%)         1,684 (70)      204 (7.8)
  Nocturnal hypertension, n (%)       1,223 (51.1)    213 (8.2)
  **Circadian rhythm**                                213 (8.2)
  Extreme dippers, n (%)              38 (1.6)        
  Dippers, n (%)                      434 (18.1)      
  Nondippers, n (%)                   1,260 (52.6)    
  Reverse dippers, n (%)              663 (27.7)      
  **24-hour BP variability**                          
  Systolic, mmHg                      15.4±4.4        183 (7)
  Diastolic, mmHg                     11.6±4.1        183 (7)
  **HBP**                                             
  **Average BP**                                      
  Systolic, mmHg                      134.1±12.3      139 (5.3)
  Diastolic, mmHg                     79.4±9.4        139 (5.3)
  **Average morning BP**                              
  Systolic, mmHg                      134.5±12.7      142 (5.4)
  Diastolic, mmHg                     79.8±9.6        142 (5.4)
  **Average evening BP**                              
  Systolic, mmHg                      134.5±12.7      142 (5.4)
  Diastolic, mmHg                     79.8±9.6        142 (5.4)
  **Day-to-day BP variability**                       
  Systolic, mmHg                      8.6±4.1         139 (5.3)
  Diastolic, mmHg                     7±7.2           139 (5.3)

**Abbreviations:** BP, blood pressure; OBP, office BP; ABP, ambulatory BP; HBP, home BP; SD, standard deviation; HR, heart rate; SBP, systolic BP; DBP, diastolic BP.

###### 

Medication information

  Variable                                All (n=2,608)   Missing
  --------------------------------------- --------------- -----------
  **History of medication**                               
  Antiplatelet                            544 (20.9)      4 (0.2)
  Anticoagulant                           14 (0.5)        4 (0.2)
  Statin                                  258 (9.9)       4 (0.2)
  Antidiabetic                            465 (17.9)      4 (0.2)
  Antihypertensive                        1,416 (54.4)    4 (0.2)
  **Medication during hospitalization**                   
  Antiplatelet                            2,523 (97)      7 (0.3)
  Anticoagulant                           200 (7.7)       8 (0.3)
  Statin                                  2,332 (89.7)    7 (0.3)
  Antidiabetic                            650 (25)        7 (0.3)
  Antihypertensive                        1,714 (65.9)    8 (0.3)
  CCB                                     1,340 (78.2)    
  ACEI                                    286 (16.7)      
  ARB                                     396 (23.1)      
  Diuretic                                113 (6.6)       
  β-Blocker                               135 (7.9)       
  Others                                  28 (1.7)        
  **Medication with discharge**                           
  Antiplatelet                            2,434 (96.3)    80 (3.1)
  Anticoagulant                           29 (1.1)        80 (3.1)
  Statin                                  2,167 (85.7)    80 (3.1)
  Antidiabetic                            547 (21.6)      80 (3.1)
  Antihypertensive                        1,731 (68.5)    80 (3.1)
  CCB                                     1,337 (77.2)    
  ACEI                                    227 (13.1)      
  ARB                                     461 (26.6)      
  Diuretic                                108 (6.2)       
  β-Blocker                               182 (10.5)      
  Others                                  9 (0.5)         
  **Medication at 3 months**                              
  Antiplatelet                            2,244 (94.7)    238 (9.1)
  Anticoagulant                           28 (1.2)        240 (9.2)
  Statin                                  1,846 (77.9)    239 (9.2)
  Antidiabetic                            485 (20.5)      239 (9.2)
  Antihypertensive                        1,600 (67.6)    240 (9.2)
  CCB                                     1,223 (76.4)    
  ACEI                                    205 (12.8)      
  ARB                                     426 (26.6)      
  Diuretic                                76 (4.8)        
  β-Blocker                               165 (10.3)      
  Others                                  8 (0.5)         

**Abbreviations:** CCB, calcium-channel blocker; ACEI, ACE inhibitor; ARB, angiotensin-receptor blocker.

###### 

ABPM- and BP diary-completion information

  Variable                             All (n=2,608)   Missing
  ------------------------------------ --------------- -----------
  **Completion of ABPM**               93%             
  **Monitoring length (hours)**                        183 (7)
  ≥24                                  1,192 (49.2)    
  ≥20, \<24                            1,141 (47.1)    
  ≥14, \<20                            54 (2.2)        
  \<14                                 38 (1.6)        
  **Successful readings**                              183 (7)
  ≥80%                                 2,144 (88.4)    
  ≥60%, \<80%                          203 (8.4)       
  \<60%                                78 (3.2)        
  Including 5--7 am duration           2,329 (96.1)    184 (7.1)
  **Completion of 3-month BP diary**   94.7%           
  **Total monitoring length (days)**                   138 (5.3)
  ≥60, \<90                            2,363 (95.7)    
  ≥30, \<60                            39 (1.6)        
  ≥7, \<30                             59 (2.4)        
  \<7                                  9 (0.3)         

**Abbreviations:** ABPM, ambulatory blood pressure monitoring; BP, blood pressure.

###### 

Clinical event outcomes

  Outcomes                           Event rate, n (%)
  ---------------------------------- -------------------
  **Recurrence rate**                
  3-month                            125 (4.8)
  1-year                             159 (6.1)
  **Combined vascular event rate**   
  3-month                            146 (5.6)
  1-year                             207 (7.9)
  **Mortality**                      
  3-month                            21 (0.8)
  1-year                             51 (2)

[^1]: These authors contributed equally to this work
